Pharmacovigilance and Appropriate Drug Use—2nd Edition
A special issue of Healthcare (ISSN 2227-9032). This special issue belongs to the section "Medication Management".
Deadline for manuscript submissions: closed (31 October 2024) | Viewed by 982
Special Issue Editor
2. Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy
Interests: pharmacology; pharmacovigilance
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Pharmacovigilance is a key public health process which helps monitor the safety of medicines and reducing the risks related to drug use in the post-marketing phase.
It works through the detection, assessment, understanding and prevention of adverse effects, or any medicine-related problems in general.
At the time of authorisation, each drug has been tested for a limited length of time in a small number of strictly selected patients. Therefore, its benefit–risk profile cannot be definitely known, and certain side effects may be detected with use in healthcare practice in a larger number of patients, for a longer period of time and with other medications.
The emergence of safety signals (new or changing safety issues) in this phase may result in regulatory action translating into modification of the terms of the marketing authorization or the way the drug can be used to protect public health. Regulatory actions include the following measures:
- Informing about the new information on the quality, safety or efficacy of a medicine;
- Advising to modify prescribing behaviour or how to use medicines to prevent or minimise risks;
- Restricting the use to exclude certain patient population.
Prior studies showed that almost all regulatory actions in the post-marketing phase have a negative impact on drug risk.
Nevertheless, the safety of a medicine is related not only to its pharmacological properties, but also the product’s quality and how it is used in clinical practice.
According to the World Health Organization (WHO), inappropriate drug use has been reported for more than 50% of all medicines in the market, resulting in various health risks and costs.
The appropriate prescribing, dispensing and use of drugs include several steps performed both by healthcare professionals (good diagnosis and good prescribing, providing the right drug to the right patient in the right formulation and posology, patient instructions and good stock management practice) and patients (good adherence/compliance).
Inappropriate drug use has been associated with an increased risk of adverse events, morbidity, mortality and healthcare utilisation.
Therefore, appropriate drug use helps prevent medication errors and increases drug safety.
Regulatory agencies can use several tools to control and manage each step of the process (from prescription to drug utilisation) in order to guarantee the appropriateness of medicine use.
The aim of this Special Issue is to provide an updated panorama of pharmacovigilance issues which result (or may result in the future) in regulatory actions and can be prevented by changing and controlling the prescribing behaviour.
Dr. Lucia Gozzo
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Healthcare is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pharmacovigilance
- safety
- adverse drug reactions
- risk
- regulatory action
- appropriateness
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
Related Special Issue
- Pharmacovigilance and Appropriate Drug Use in Healthcare (11 articles)
